ClinicalTrials.gg
RecruitingNCT05147467Updated Mar 27, 2026

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

A Phase 2 interventional study of APG2575 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Ascentage Pharma Group Inc.. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.

Planned enrollment
57th of 105
75 · median 89
Started
2021
with 15 others
Phase 2
21 of 108
9 open now
Primary completion
2026-12
later than 25 of 59 live
Registered
64th of 108
by date
Lead sponsor
3 of 108
Ascentage Pharma Group Inc.

Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 57th largest by planned enrollment of the 105 interventional ones that give a count, is one of 16 that started in 2021, is one of 21 in phase 2, reaches primary completion later than 25 of the 59 other live ones, and was the 64th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

Read the detailed description

This is an single-arm, open-label, multi-center, pivotal registration Phase II study of efficacy and safety of APG-2575 as a single agent in relapsed/refractory CLL/SLL patients.

This study plans to enroll approximately 75 CLL/SLL subjects who have failed or are intolerant to prior immunochemotherapy and BTK inhibitor therapy. Eligible subjects will receive APG-2575 600mg, orally administered once daily (QD), within half an hour of a low-fat meal, for a cycle of 28 days. Participants will continue to accept APG - 2575 until the "end of treatment" that are consistent with the provisions in the solution of the termination of any specified standards.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • APG-2575
  • Lisaftoclax
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet each of the following inclusion criteria are eligible to participate in this study:

  1. Age ≥18 years old.
  2. confirmed CLL/SLL according to the 2018 revised IWCLL NCI-WG guidelines, subject with or splenomegaly due to CLL.
  3. Expected survival is at least 12 weeks.
  4. , recurrent, or intolerant to BTK inhibitors and immunochemotherapy,or treatment with BTK inhibitors fails and is not suitable for immunochemotherapy.
  5. (ECOG) Performance Status (PS): 0 -2.
  6. Ability to understand and willingness to sign a written form approved by EC committee (the consent form must be signed by the patient prior to any screening or study-specific procedures).
  7. Willingness and ability to comply with study procedures and follow-up examination.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:

  1. Prior history of hematopoietic stem cell transplantation, adoptive cell immunotherapy or autologous hematopoietic stem cell transplantation within 24 months.
  2. Failure to recover adequately, at the discretion of the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
  3. Received Bcl-2 inhibitor treatment.
  4. Invasive NHL transformation or central nervous system (CNS) involvement has occurred.
  5. Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of treatment.
  6. Within 2 years before entering the study, the subject had a history of active malignant tumors other than CLL / SLL, except that:

    • Fully treated cervical carcinoma in situ;
    • Completely resected basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Confinement and resection of previously cured (or other treatment).
  7. Any other condition or circumstance that would, at the discretion of the investigator, make the patient unsuitable for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    APG-2575 single agent in Relapse/Refractory CLL/SLL

    APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.

    Drug: APG2575

Interventions

  • APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined by Complete Remission (CR)+ CR with incomplete marrow recovery (CRi) + Partial Remission (PR) (according to NCI-WG CLL(2018)) and by CR+PR ( according to Lugano (2014)).Response will be evaluated every 2 cycles (8 weeks) till complete treatment or one month after last dose.

    Time frame: Up to 9 months after the last subject enrolled.

Secondary outcomes

  1. Progress Free Survival (PFS)

    PFS is defined as the time from the first administration to disease progression(PD) or death from any cause.

    Time frame: Up to 9 months after the last subject enrolled.

  2. Time To Progression (TTP)

    TTP is defined as the time from the first administration to PD.

    Time frame: Up to 9 months after the last subject enrolled.

  3. Time To Response (TTR)

    TTR is defined as the time from the first administration to the subjects' first CR, CRi, or PR.

    Time frame: Up to 9 months after the last subject enrolled.

  4. Duration of Response (DOR)

    DOR is defined as the time from the subject's first CR, CRi, or PR to PD or death from any cause.

    Time frame: Up to 9 months after the last subject enrolled.

  5. Overall Survival (OS)

    OS is defined as the time from the first administration to death.

    Time frame: Up to 9 months after the last subject enrolled.

  6. the time of half absolute lymphocyte value (ALC)

    The time of half absolute lymphocyte value (ALC) is defined as the time from the first administration to 50% reduction of ALC of baseline.

    Time frame: Up to 9 months after the last subject enrolled.

  7. Adverse events

    Adverse events (AE) and serious adverse events (SAE) will be graded according to NCI CTCAE Version 5.0.

    Time frame: Up to 9 months after the last subject enrolled.

  8. Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) will be assessed on all participants with APG-2575 treatments.

    Time frame: Up to 4 cycles (each cycle is 28 days).

  9. Area under the plasma concentration versus time curve (AUC)

    Area under the plasma concentration versus time curve (AUC) will be assessed on all participants with APG-2575 treatments.

    Time frame: Up to 4 cycles (each cycle is 28 days).

Other outcomes

  1. Minimal Residual Disease (MRD) negative rate

    To observe the proportion of subjects with MRD negative status in bone marrow, peripheral blood, one or both.

    Time frame: Up to 9 months after the last subject enrolled.

  2. Bcl-2 expression

    Potential biomarkers to be evaluated included the association of Bcl-2 expression with the efficacy of APG-2575 monotherapy.

    Time frame: Up to 9 months after the last subject enrolled

07

Study locations

4 of 11 sites recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Yang Liang, Postdoc · Contact
    • Yang Liang, Postdoc · Principal investigator
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
    Not yet recruiting
    • Rui Huang, M.D., Ph.D. · Contact
    • Rui Huang, M.D., Ph.D. · Principal investigator
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
    Recruiting
    • Ru Feng · Contact
    • Ru Feng, M.D. · Principal investigator
  • Hainan General Hospital
    Haikou, Hainan 570311, China
    Not yet recruiting
    • Li'e Lin, M.D. · Contact
    • Li'e Lin, M.D. · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
    • Keshu Zhou, M.D., Ph.D. · Contact
    • Keshu Zhou, M.D., Ph.D. · Principal investigator
  • Union Hospital medical college Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Guohui Cui, M.D. · Contact
    • Guohui Cui, M.D. · Principal investigator
  • The First Affilated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
    Not yet recruiting
    • Caixia Li, M.D., Ph.D. · Contact
    • Caixia Li, M.D., Ph.D. · Principal investigator
  • People's hospital of Jiangsu Province
    Suzhou, Jiangsu, China
    Not yet recruiting
  • The First Affilated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Not yet recruiting
    • Fei Li, M.D., Ph.D. · Contact
    • Fei Li, M.D., Ph.D. · Principal investigator
  • Institute of blood transfusion of Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 215127, China
    Not yet recruiting
    • Tingyu Wang, M.D., Ph.D. · Contact
    • Tingyu Wang, M.D., Ph.D. · Principal investigator
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hanzhou, Zhejiang 310003, China
    Not yet recruiting
    • Jie Jin, M.D., Ph.D. · Contact
    • Jie Jin, M.D., Ph.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 60 months is close to that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 7, 2021
StartActual
Dec 28, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05147467
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Dec 28, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Zi Chen, Doctor
Contact
Zi.Chen@ascentage.com
+8618117275173
Min Yu, Doctor
Contact
Min.Yu@ascentage.com
+8615000679101
Yifan Zhai, M.D., Ph.D.
study director · Ascentage Pharma Group Inc.
Jianyong Li, M.D.
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisaftoclax

Start the discussion